Oral-B and Straumann Partner on a Landmark Alliance for Scientific Education to Improve the Periodontal and Peri-Implant Health of Patients Worldwide
Oral-B and Straumann, two of the world’s leading oral care companies, are proud to announce a new global alliance whose purpose is to elevate the importance of prevention in periodontal and peri-implant health. The alliance will set new standards in quality scientific education for dental professionals and help their patients achieve better long-term outcomes.
The Oral-B Straumann alliance has a long-term goal of delivering a holistic program of scientific events, professional courses, webinars and publications, co-created with and delivered by the world’s leading experts and thought leaders in dentistry.
The alliance will be launched on 17th June 2022 with a Sponsored Scientific Session at EuroPerio10 Copenhagen – the world’s leading congress in periodontology and implant dentistry – where both companies will also present their recent innovations for periodontal and peri-implant patients: Straumann Biomaterials solutions ranging from enhanced wound healing and bone regeneration to soft-tissue management and wound care and Oral-B iO Specialized Clean brush head, Oral-B iO10 & iOsense to empower patients in effective self-care.
“As patients around the world invest in dental implants, they need to recognize that self-care around implants is just as important as around their natural teeth. The Oral-B/Straumann Alliance will play an important role in enabling ongoing dialogue between dental professionals and their patients so both understand the most up to date science on prevention of implant-related diseases and promotion of periodontal health,” says J. Leslie Winston, Vice President, Global Health Care R&D, Procter & Gamble.
Arik Zucker, Vice President, Global Head of Biomaterials, Straumann Group, adds: “Prevention of tooth or implant loss is for many years an important topic for us in the Straumann Group. As one of the world’s leading dental implant companies, we work closely with experts from the research and clinical fields to address the issues caused by peri-implantitis and periodontitis. The Alliance with Oral-B complements our efforts and offers a solid ground for further scientific and educational activities that will enable more dental professionals to improve their patients’ lives.”
Oral-B & Straumann Alliance: Partnering to Amplify the Importance of Prevention
The vision for the Oral-B Straumann Alliance is ambitious: an unwavering commitment to amplifying the importance of prevention through scientific education, helping dental professionals and their implant and periodontal patients achieve better outcomes.
Starting with the Sponsored Scientific Session at Europerio10 in Copenhagen on 17th June 2022, the alliance will be rolled out over a series of scientific exchange activities that include a forthcoming scientific symposium at the American Academy of Periodontology annual meeting in October 2022, as well as continuing education courses, webinars and publications- all developed with and delivered by the world’s leading experts and thought leaders- focusing on the importance of preventive clinical and self-care for the life cycle of the implant and general periodontal health.
The Sponsored Scientific Session “Limiting periodontal and peri-implant diseases during and beyond the pandemic: from the chair to self-care.” will be presented at Europerio10 by Dr. Martina Stefanini (University of Bologna), Prof Giorgio Pagni (University of Milan) and Prof Filippo Graziani (University of Pisa). Reflecting on the importance and potential impact of the Oral-B Straumann alliance, Prof Graziani remarked: “I strongly believe that with the changes in the society and patients’ behaviors it is fundamental to provide a large array of solutions for general health. There are so many opportunities that any patient may get confused by the plethora of products and indications. Thus, this alliance should be cherished in order to simplify the life of our patients and provide additional benefits for their health.”
Periodontal Disease: the #1 cause of tooth loss
Tooth loss is a major global oral health concern: 69 % of 35-44-year-olds in the US have lost at least one permanent tooth1 while in Europe 30 % of 65-74-year-olds have no natural teeth left2. With periodontal disease being the number one cause of tooth loss in adults-and prevalent in up to 50 % of the global adult population- its impacts can have a detrimental effect on the quality of a patient’s life, with a growing volume of scientific evidence that consistently highlights the association between periodontal disease and a number of systemic conditions, such as Type 2 diabetes, cardiovascular disease and Alzheimer’s disease.3
The economic impacts of periodontal disease (both on the individual and society as a whole) are no less significant: A single tooth implant costs 2,000-5,000 euros and to protect their investment, patients must be educated on how to remove plaque (the dominant risk factor for oral disease) and prevent periodontal & peri-implant diseases, with dental professionals playing a central role in this process.
Prevention Pays Off
Studies show that the removal of 80-85 % of oral biofilm twice a day as part of a patient’s self-care routine can maintain oral and implant health.4 And as we emerge from the pandemic prevention of periodontal disease is more important now than ever, with recent research finding that Covid-19 patients with periodontitis are 3.5x more likely to be admitted to intensive care and 9x more likely to die than Covid-19 patients with healthy gums.5 Beyond the significant personal benefit to the patient, recent studies have also shown that eliminating the burden of gingivitis and increasing the diagnosis and treatment rate of periodontitis to 90% in 6 European countries shows a positive return on investment for society over a 10-year period.6
Trusted Science, Trusted Brands, Indispensable Partners for Dental Professionals
Both Oral-B & Straumann are innovation leaders in their respective fields: the former with its range of proven personal oral hygiene products – the #1 dentist recommended brand worldwide – and the latter as the world-leading brand for confidence in esthetic dentistry and a gold standard in implantology. With their extensive portfolios of breakthrough oral care products and biomaterials, Oral-B and Straumann will support the launch of the alliance by presenting to dental professionals an upcoming range of new innovations for successful patient outcomes:
Oral-B iO Specialized Clean Brush Head:Brushing personalized to the needs of Implant Patients
The highly anticipated Specialized Clean brush head – with its distinctive bristle field designed with dental professionals exclusively for the Oral-B iO series of electric rechargeable toothbrushes – combines oscillation-rotation with the gentle energy of microvibrations to effectively reach and clean around implant restorations and other hard-to-reach areas that require special focus.
Findings from a recent case study of implant patients who used the Oral-B iO9 round brush heads together with the Specialized Clean brush head showed a 62.7 % reduction in plaque 8 weeks after switching to iO from their regular toothbrush; in line with previously published research showing the superior oral hygiene benefits in favour of Oral-B iO versus a manual toothbrush. In a recent study, 3 times more patients with swollen gums who used Oral-B iO were categorized as generally healthy over an 8-week period compared to those patients using a manual toothbrush.7
Oral-B iO10 with iOsense: Technology for better self-care
Launching in September 2022, Oral-B iO10 with iOsense offers real-time coaching via Artificial Intelligence and the Oral-B app, making it even simpler to establish good oral hygiene habits without the need to bring your phone into the bathroom. The iOsense™ Smart Charger personalizes your clean with live coaching to guide how, when and where you brush by providing real-time feedback on your brushing via the LEDs built into the charger, ensuring the user brushes thoroughly, with optimal pressure and for the dental professional recommended duration.
Research shows a positive correlation between app usage and improved oral hygiene.8 And a recent analysis of 16.7 million anonymized real world brushing sessions using the Oral-B app and Oral-B® smart-connected oscillating-rotating toothbrushes found that real-time feedback using Position Detection resulted in:9
- Excellent brushing thoroughness: with an average of 94% of brushing zones covered and with 8 out of 10 brushing sessions producing complete coverage.
- Longer Brushing: Brushing sessions with real-time app feedback lasted on average 2m43s, 21.6 % longer than brushing sessions without the app and helping users ensure they brush for the dental professional recommended 2 minutes. With the average brushing session with a manual toothbrush reported to be just 46 seconds long there has never been a better time adopt interactive brush technology to help establish better brushing behaviors.
Straumann Biomaterials: proven technologies to help dental professionals set their patients up for success
Equally significant is the contribution to dentistry by Straumann, a global leader in the field of dental implants and an important player in the biomaterials market. Offering the industry’s most comprehensive biomaterials portfolio, Straumann provides dental professionals with a unique range in oral regeneration that covers a large range of indications, from enhanced wound healing and bone regeneration to soft-tissue management and wound care:
- Straumann® Emdogain®: a unique gel containing enamel matrix derivative with an impressive scientifical background of over 1000 publications10, including multiple 10-year follow-up studies11, and over 25 years of clinical experience. Based on its success and thanks to a new, shorter, and thinner applicator, Emdogain® FL can now be applied by specialists, general practitioners, and dental hygienists in a flapless approach connected to the hygiene phase of the periodontal treatment.12
- Jason® membrane – a pericardium-based collagen membrane with a long barrier function, tensile strength, and easy handling.13,14
- Straumann® XenoGraft – an easy-to-handle bovine bone graft that provides long-term volume stability.
- Labrida BioClean™ – a proven solution for effective debridement of teeth and dental implant surfaces as part of maintenance or treatment protocols provided by specialists, general practitioners, and even dental hygienists.15,16
About Oral-B®
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About The Straumann Group
The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs more than 9000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.
__________________________
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028797/#:~:text=Statistics%20provided%20by%20the%20American,of%20their%20permanent%20teeth6 (accessed April 2022)
2https://www.euro.who.int/en/health-topics/disease-prevention/oral-health/data-and-statistics#:~:text=Dental%20caries%20and%20severe%20periodontal,cases%20per%20100%20000%20people (accessed April 2022)
3https://www.scientificamerican.com/custom-media/a-scientific-approach-to-cleaning-your-mouth/ (accessed April 2022)
4 Wingrove S. Why personalized oral hygiene technology matters. Compend Contin Educ Dent. 2022;43(suppl 1):1-4
5 Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: A case-control study. J Clin Periodontol 2021; 48(4): 483-91
6 Bouchard, Carner, Carter et al., Time to take gum disease seriously, The Economist Intelligence Unit, 2021
7 Grender J, Goyal CR, Qaqish J, Adam R. Int Dent J 2020 70 (Suppl 1) S7-S15
8 Tonetti, MS, Deng, K, Christiansen, A, et al.. J Clin Periodontol. 2020; 47: 1219– 1226.
9 Thurnay S, Adam R, Meyners M. Oral Health Prev Dent. 2022 Jan 20;20(1):1-10. doi: 10.3290/j.ohpd.b2572911. PMID: 35049247
10 According to PUBMED search for “Emdogain” or “enamel matrix derivative”
11 Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2008 Sep;35(9):817-24
12 Graziani F, Gennai S, Petrini M, Bettini L, Tonetti M. Enamel matrix derivative stabilizes blood clot and improves clinical healing in deep pockets after flapless periodontal therapy: A Randomized Clinical Trial. J Clin Periodontol. 2019 Feb; 46(2):231-240.
13 Rothamel et al. 2012, Biocompatibility and Biodegradation of a Native, Porcine Pericardium Membrane. Results from in vitro/in vivo Examination, J. Int J Oral Maxillofac Implants, 27(1):146-54.
14 Barbeck et al. 2015, Porcine dermis and pericardium-based, non-cross-linked materials induce multinucleated giant cells after their in vivo implantation: A physiological reaction? J Oral Implantol., 41(6):e267-81.
15 Wohlfahrt JC, Aass AM, Koldsland OC: Treatment of peri-implant mucositis with a chitosan brush-A pilot randomized clinical trial. Int J Dent Hyg 2019;17:170-176.
16 Wohlfahrt JC, Evensen BJ, Zeza B, Jansson H, Pilloni A, Roos-Jansaker AM, Di Tanna GL, Aass AM, Klepp M, Koldsland OC: A novel non-surgical method for mild peri-implantitis- a multicenter consecutive case series. Int J Implant Dent 2017;3:38.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006268/en/
Contact information
Corporate:
Procter & Gamble GmbH, Sulzbacher Straße 40, 65824 Schwalbach am Taunus,
Boris Atlas
atlas.b@pg.com
Institut Straumann AG, Peter Merian-Weg 12, CH-4052 Basel, Switzerland
Laurentiu Motoc
laurentiu.motoc@straumann.com
Media:
MSL Germany, Otto-Messmer-Straße 1, 60314 Frankfurt am Main
Christina Meyer
christina.meyer@mslgroup.com
Procter & Gamble IO sa, 47 route de St-Georges, 1213 Petit Lancy, Switzerland
Paola Mulas
mulas.p@pg.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press Release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration17.12.2025 20:47:00 CET | Press Release
Picsart, the world’s leading digital creation platform with over two billion downloads and more than 100 million monthly active users, is partnering with Zazzle, the global leader in customized products and designs, to deliver an end-to-end printing solution for Picsart users. The new “vibe-design-to-print” integration works seamlessly with Picsart’s recently expanded suite of AI products, including AI Assistant and Flows, enabling creators to ideate, iterate, design, and bring their work to life as physical art and products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217882832/en/ Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration “At Picsart, our mission has always been to give creators the tools they need to bring their ideas to life,” said Hovhannes Avoyan, Founder and CEO of Picsart. “As we enter what we believe will be the year of the creative entrepreneur, creators are i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
